An update on the development of advanced drug delivery systems for the treatment of hyperthyroidism
| dc.contributor.author | Bairagi U.; Mishra B. | |
| dc.date.accessioned | 2025-05-23T11:23:31Z | |
| dc.description.abstract | Thyroid hormone production and functioning activities in the human body are interrupted in hyperthyroidism, which can be hereditary or acquired. Hyperthyroidism and also its related illnesses have attained growing public health problems across the world. To date, a variety of approaches have been used to manage and cure various disorders, such as systemic medication therapy and surgical methods. Existing therapies and alternatives for treating these illnesses, however, are limiting and inadequate, particularly when it comes to treatment response. As a result, it is essential to use efficient drug delivery systems to successfully treat hyperthyroidism illnesses while also reducing adverse drug effects. In this book chapter, we have outlined different options for the treatment of hyperthyroidism, such as conventional drug delivery, including oral and local delivery, responsive drug strategy, and nanocarriers-based drug delivery. © 2022 Elsevier Inc. All rights reserved. | |
| dc.identifier.doi | https://doi.org/10.1016/B978-0-323-99616-7.00003-7 | |
| dc.identifier.uri | http://172.23.0.11:4000/handle/123456789/9120 | |
| dc.relation.ispartofseries | Drug Delivery Systems for Metabolic Disorders | |
| dc.title | An update on the development of advanced drug delivery systems for the treatment of hyperthyroidism |